Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6193791 | 0.97 | BAZ2B (0.63) | BAZ2BMAPK14RAB9ANPC1CYP1A2 | |
| SCHEMBL2000310 | 0.92 | BAZ2B (0.55) | BAZ2BRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL9145386 | 0.84 | BAZ2B (0.59) | BAZ2BMAPK14KMT2AHIF1A | |
| SCHEMBL6240743 | 0.83 | RAB9A (0.46) | BAZ2BRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL6212186 | 0.83 | BAZ2B (0.57) | BAZ2BMAPK14RAB9ANPC1ALDH1A1 | |
| SCHEMBL6238287 | 0.83 | NPC1 (0.46) | BAZ2BRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL31298843 | 0.82 | BAZ2B (0.67) | BAZ2BMAPK14RAB9ANPC1HIF1A | |
| SCHEMBL6028885 | 0.82 | BAZ2B (0.67) | BAZ2BMAPK14RAB9ANPC1HIF1A | |
| SCHEMBL30612414 | 0.80 | BAZ2B (1.00) | BAZ2BMAPK14RAB9ANPC1CYP1A2 | |
| SCHEMBL315269 | 0.80 | BAZ2B (1.00) | BAZ2BMAPK14RAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338487-B2 | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338487-B2 | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | ORAPHARMA, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | ORAPHARMA, INC. | 2011-08-25 | — | — | US | disclosed |
| US-7960436-B2 | Therapy and prophylaxis of diseases and disorders such as seizure disorders; [1-Amino-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960436-B2 | Therapy and prophylaxis of diseases and disorders such as seizure disorders; [1-Amino-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960436-B2 | Therapy and prophylaxis of diseases and disorders such as seizure disorders; [1-Amino-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | SCN1B, SCN1A, SCN4A | BAZ2B 1954/4885MAPK14 3174/4885RAB9A 1815/4885 |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | SCN1B, SCN1A, SCN4A | BAZ2B 1807/4885MAPK14 3041/4885RAB9A 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.